Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

ÁãÀÇ ÀüÀ̼º °£¾Ï ¸ðµ¨¿¡¼­ ÀÚ°¡ Á¾¾ç ¹é½ÅÀ» ÀÌ¿ëÇÑ ¸é¿ª Ä¡·á Specific Immunotherapy Using tautologous Tumor Vaccine Treats Murine Metastatic Hepatic Cancer

´ëÇѾÏÇÐȸÁö 1999³â 31±Ç 2È£ p.360 ~ 366
¼­±¤¿í, À̺ÀÈ£, MichaelA.Choti,
¼Ò¼Ó »ó¼¼Á¤º¸
¼­±¤¿í (  ) 
¾ÆÁÖ´ëÇб³ ÀÇ°ú´ëÇÐ ¿Ü°úÇб³½Ç

À̺ÀÈ£ (  ) 
¾ÆÁÖ´ëÇб³ ÀÇ°ú´ëÇÐ ¿Ü°úÇб³½Ç
 ( MichaelA.Choti ) 
Á¸½ºÈ©Å²½º´ëÇб³ ÀÇ°ú´ëÇÐ ¿Ü°úÇб³½Ç

Abstract

¼­·Ð
ÀÚ°¡ Á¾¾ç ¼¼Æ÷(autologous tumor cell)¸¦ ÀÌ¿ëÇÏ¿©, Á¾¾ç ¹é½ÅÀ» ¸¸µé·Á´Â ¹æ¹ýµéÁß¿¡¼­,
cytokine À¯ÀüÀÚ¸¦ ¹ÙÀÌ·¯½º¿Í °°Àº ¸Å°³Ã¼¸¦ ÀÌ¿ëÇÏ¿© Á¾¾ç ¼¼Æ÷ ³»·Î ÇüÁú µµÀÔ
(transduction)½ÃÅ°´Â ¹æ¹ýÀÌ ÇöÀç °¡Àå ³Î¸® »ç¿ëµÇ´Â ½ÇÇè ¸ðµ¨À̸ç, ÀÓ»óÀÀ¿ëÀ» À§ÇØ Á¦
1»ó ¿¬±¸°¡ ÁøÇà ÁßÀÎ ºÐ¾ßÀÌ´Ù. ÀÚ°¡ Á¾¾ç ¹é½ÅÀº ¾Ï ¼¼Æ÷¸¦ ÀÌÇüÈ­(xenogenization)½ÃÅ´À¸
·Î¼­, ³»¼ºÀ» º¸ÀÌ´ø ¸é¿ª ü°è·Î ÇÏ¿©±Ý Á¾¾çÀ» ÀνĽÃÅ°°Ô ÇÏ´Â ¹æ¹ýÀ¸·Î, Á¾¾ç ƯÀÌ Ç׿ø
¿¡ ´ëÇÑ ¼¼ºÎÀûÀÎ Á¤º¸ Á¦°øÀÌ ÇÊ¿ä ¾ø´Ù´Â ÀåÁ¡À» °¡Áø´Ù. ±×·¯³ª cytokineµéÀÌ ¼¼Æ÷ ÁÖÀ§
ÀÇ ¾ÆÁÖ ÀÛÀº ¹Ý°æ ³»¿¡¼­¸¸ È¿°ú¸¦ ³ªÅ¸³»±â ¶§¹®¿¡, paracrine È¿°ú¸¦ ÀÌ¿ëÇÑ Á¾¾ç ¹é½ÅÀÌ
¶ó°í ºÎ¸£±âµµ ÇÑ´Ù.
¸¹Àº cytokineµéÀÌ ½ÇÇèÀûÀ¸·Î ÀÌ¿ëµÇ¾î, ÇüÁúµµÀÔ ÈÄ ¸¸µé¾îÁø »õ·Î¿î ¾Ï ¼¼Æ÷°¡ ü³»¿¡
¼­ ¾ÏÀ¸·ÎÀÇ ÁøÇàÀº µÇÁö ¾ÊÀ¸¸é¼­ Åõ¿©µÈ ¼÷ÁÖ·Î ÇÏ¿©±Ý ±× Á¾¾ç¿¡ ´ëÇØ Àü½ÅÀûÀÎ ¸é¿ª´É
À» °¡Áö°Ô ÇÏ´Â °ÍÀÌ °üÂûµÇ¾î ¿ÔÀ¸³ª, ±× Áß °ú¸³¼¼Æ÷ °Å½Ä¼¼Æ÷-±ºÃ¼ ÀÚ±Ø ¹°Áú
(granulocyte macrophage-colony stimulating factor, GM-CSF)¿¡¼­ °¡Àå °­·ÂÇÑ Ç×¾Ï È¿°ú
¸¦ °üÂûÇÏ¿´´Âµ¥, ÀÌ´Â Àü¹®ÀûÀÎ Ç׿ø Á¦½Ã ¼¼Æ÷µé, ƯÈ÷ ¼ö»ó ¼¼Æ÷(dendritic cell)ÀÇ ºÐÈ­¸¦
ÃËÁøÇÔÀ¸·Î¼­, ¸é¿ª ü°èÀÇ Ãʱâ´Ü°èºÎÅÍ È°¼ºÈ­½ÃÅ°´Â ±âÀü ¶§¹®ÀÌ´Ù. GM-CSF À¯ÀüÀÚ¸¦
ÇüÁú µµÀÔÇÑ ¼¼Æ÷µéÀÌ µ¿¹° ½ÇÇè ¸ðµ¨¿¡¼­ °üÂûµÈ Ç×¾Ï È¿°úµéÀ» ±âÃÊ·Î, ¾Ç¼º Èæ»öÁ¾°ú ½Å
Àå¾Ï ȯÀÚ µî¿¡ ´ëÇØ ÀÓ»ó ½ÇÇèÀ» °èȹ ÁßÀÌÁö¸¸, ÀÓ»ó Àü ½ÇÇè ¸ðµ¨µéÀÌ ÀÓ»óÀûÀ¸·Î ¿¬°ü
ÀÌ ¾ø´Â ÇǺγª ¿¬ºÎ Á¶Á÷¿¡ ´ëÇÑ ½ÇÇèÀ̾úÀ¸¸ç, ´õ±¸³ª ÀÌ¹Ì ¸¸µé¾îÁø ¾Ï¿¡ ´ëÇÑ Ç×¾Ï È¿
°ú¸¦ °üÂûÇÏ·Á´Â ½ÇÇèÀÌ °ÅÀÇ ¾ø¾î, ÀÓ»óÀûÀ¸·Î À¯ÀÇÇÑ ¿¬°üÀÌ ÀÖ´Â ½ÇÇè ¸ðµ¨¿¡¼­ÀÇ Ç×¾Ï
È¿°ú¿Í ¼³Á¤µÈ ¾Ï¿¡ ´ëÇÑ Ç×¾Ï È¿°ú¸¦ °üÂûÇÏ´Â °ÍÀÌ ¸Å¿ì Áß¿äÇÏ´Ù.
ÀúÀÚµéÀº ÁãÀÇ ÀüÀ̼º °£¾Ï ¸ðµ¨¿¡ ´ëÇØ GM-CSF À¯ÀüÀÚ¸¦ ÇüÁú µµÀÔÇÑ ÁãÀÇ ´ëÀå¾Ï ¼¼
Æ÷ÁÖÀÇ Ç×¾Ï È¿°ú¸¦ °üÂûÇÏ¿´°í, ¼³Á¤µÈ ÀüÀ̼º °£¾Ï¿¡ ´ëÇÑ ½ÇÇè°á°ú¿Í ÇÔ²² º¸°íÇÏ´Â ¹Ù
ÀÌ´Ù.

Purpose : Antitumor effect of granulocyte macrophage colony-stimulating factor
(GM-CSF)-producing murine colon cancer cells was elucidated against intrahepatic
challenge of parental cancer cells, which is clinically relevant tumor model.
Materials and Methods : Using a model of liver metastasis by intrahepatic challenge
of CT-26 murine colon carcinoma cells to syngeneic BALB/c mice, GM-CSF producing
cells were given as a intradermal vaccine either 14 days prior to hepatic challenge, or in
animals with established tumors. Tumor volume and survival were determined.
Results : Animals receiving vaccination showed significant systemic protection against
the hepatic challenge of parental tumor cells, and in animals with established hepatic
tumors significant response was observed with some prolongation in survival.
Conclusion : It is concluded that CM-CSF-producing autologous tumor vaccine was
effective for the protection of host against the metastatic hepatic tumor model Even
though its efficacy against the established tumor was not as significant as in protection,
CM-CSF producing autologous tumor vaccine can provide support for the specific
immunotherapy for the metastatic liver cancer.

Å°¿öµå

Autologous tumor vaccine; Hepatic metastases; GM-CSF;

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

 

µîÀçÀú³Î Á¤º¸

KoreaMed
KAMS